Eli Lilly’s Selpercatinib (LOXO-292) Receives Priority Review Status for the Treatment of RET-Driven Cancer Indications

 Eli Lilly’s Selpercatinib (LOXO-292) Receives Priority Review Status for the Treatment of RET-Driven Cancer Indications

Eli Lilly’s Selpercatinib (LOXO-292) Receives Priority Review Status for the Treatment of RET-Driven Cancer Indications

Shots:

  • The NDA is based on P-I/II LIBRETTO-001 study assessing selpercatinib in patients with advanced RET fusion+ NSCLC & thyroid cancer and RET-mutant MTC. The study included P-I as dose-escalation phase and P-II dose-expansion phase
  • Selpercatinib has received FDA’s BT and ODD for the above mention indications and is currently being evaluated in two P-III studies LIBRETTO-431 for patients with treatment-naïve RET fusion+ NSCLC, and LIBRETTO-531 for patients with treatment-naïve RET-mutant MTC
  • Selpercatinib is a highly selective and potent investigational therapy for multiple cancer indications harboring abnormalities in the RET kinase with its anticipated PDUFA date in Q3’2020

Click here to­ read full press release/ article | Ref: Eli Lilly | Image: Live Mint

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post